The results demonstrated that PLAUR expression was significantly positively correlated with CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, and TIGIT, indicating that targeting PLAUR might increase the efficacy of immunotherapy in NSCLC. The gene discussed is TIGIT; the disease is non-small cell lung carcinoma.